Category Archives: Embryonic Stem Cells


Stem Cell Clinic > Embryonic Stem Cells

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

By Embryonic Stem Cells

Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements and Consolidated Financial Statements as well as the report on non-financial matters for the 2024 financial year. The 1,072 shareholders in attendance, together with the votes represented by the independent proxy, represented 75.73% of shares registered with voting rights.

Read the original:
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

FluidForm Bio™ Advances Vascularized Tissue Engineering with New FRESH™ 3D Bioprinting Breakthrough

By Embryonic Stem Cells

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced a major advancement in vascularized tissue engineering. A newly published study in ACS Biomaterials Science & Engineering demonstrates how FRESH™ 3D bioprinting, combined with sacrificial gelatin microparticles, significantly enhances cell viability in thick tissue constructs by improving nutrient diffusion and enabling scalable perfusion strategies.

See the rest here:
FluidForm Bio™ Advances Vascularized Tissue Engineering with New FRESH™ 3D Bioprinting Breakthrough

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage…

By Embryonic Stem Cells

MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibitors (ICI) in first line small cell lung cancer (SCLC) patients with extensive disease, sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. This is the first clinical trial testing the combination of iadademstat with ICI.

More:
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage...

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

By Embryonic Stem Cells

HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025.

Read more:
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

Aspargo Labs CEO to Participate in Panel Discussion at the American Urological Association Innovation Nexus Conference

By Embryonic Stem Cells

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a Pharmaceutical and MedTech company focused on converting the world's most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced that Michael Demurjian, CEO & Chairman, will participate in a panel discussion at the American Urological Association (AUA) Innovation Nexus Conference in Las Vegas, Nevada, taking place on April 25, 2025.

Originally posted here:
Aspargo Labs CEO to Participate in Panel Discussion at the American Urological Association Innovation Nexus Conference

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

By Embryonic Stem Cells

WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates.

See original here:
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025

By Embryonic Stem Cells

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort

Excerpt from:
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025

←